Lilly and Camurus Enter $870M Collaboration for Long-Acting FluidCrystal® Incretin Therapies in Cardiometabolic Health

June 3, Camurus and Eli Lilly and CompanySigning cooperation and licensing agreements,Granting Eli Lilly the global exclusive rights for research, development, manufacturing, and commercialization of long-acting incretin products based on Camurus' FluidCrystal technology., for cardiometabolic health.

The agreement includes up to four proprietary drug compounds from Eli Lilly. Selected from GIP/GLP-1 receptor agonists, GIP/glucagon/GLP-1 receptor agonists, and options including amylin receptor agonists. This technology is expected to extend the dosing interval of Eli Lilly's GLP-1 class drugs, thereby improving patient compliance.

The partnership focuses on developing long-acting therapies based on Camurus' FluidCrystal® technology and Eli Lilly and Company's proprietary drug compounds.

Camurus is eligible to obtainUp to $870 million in potential development and sales milestone payments, along with mid-single-digit royalties.

Camurus CEO and President Fredrik Tiberg said:“"We are delighted to partner with Eli Lilly and Company to provide innovative, long-acting treatment options for people living with obesity, diabetes, and other serious chronic diseases. By collaborating with Eli Lilly and Company, a global leader in metabolic diseases, we can rapidly expand our reach within indication areas affecting hundreds of millions of people using our FluidCrystal technology, while maintaining our commercial focus on central nervous system and rare diseases."

Camurus AB (publ) (referred to as Camurus)

The company's FluidCrystal® technology significantly improves treatment adherence by extending the drug release time and reducing the frequency of medication for patients.

FluidCrystal Technology

The technology has been commercially and regulatory validated through market approvals and product sales in Europe, the United States, and Australia.Especially in the treatment of opioid dependence, Buvidal®, a product based on FluidCrystal® technology launched by Camurus, has been marketed in multiple countries, helping patients effectively overcome drug dependency.

Camurus AB is developing a once-a-month semaglutide injection using the technology, currently in Phase 1 clinical trials.。

Buvidal® is a long-acting buprenorphine injection for the treatment of opioid dependence, suitable for adults and adolescents aged 16 and above, administered weekly or monthly by healthcare professionals. Brixadi® is the trademark of Buvidal® in the United States, used for treating patients with moderate to severe opioid use disorder.

End

---

Statement:All articles published on this official account (including original and reprinted articles) are intended to convey more information, and the sources and authors are credited. This official account welcomes sharing in friend circles or large groups.Reproduction in any form by media or institutions without authorization is prohibited.。

Reprint/Business/Contribution| Contact WeChat15618157102（sum_Gmi）

Business Cooperation

Call for Papers

Click to learn more